An Extension of Deep Pathway Analysis: A Pathway Route Analysis Framework Incorporating Multi-dimensional Cancer Genomics Data

Recent breakthroughs in cancer research have come via the up-and-coming field of pathway analysis. By applying statistical methods to prior known gene and protein regulatory information, pathway analysis provides a meaningful way to interpret genomic data. While many gene/protein regulatory relationships have been studied, never before has such a significant amount data been made available in organized forms of gene/protein regulatory networks and pathways. However, pathway analysis research is still in its infancy, especially when applying it to solve practical problems. In this paper we propose a new method of studying biological pathways, one that cross analyzes mutation information, transcriptome and proteomics data. Using this outcome, we identify routes of aberrant pathways potentially responsible for the etiology of disease. Each pathway route is encoded as a bayesian network which is initialized with a sequence of conditional probabilities specifically designed to encode directionality of regulatory relationships encoded in the pathways. Far more complex interactions, such as phosphorylation and methylation, among others, in the pathways can be modeled using this approach. The effectiveness of our model is demonstrated through its ability to distinguish real pathways from decoys on TCGA mRNA-seq, mutation, Copy Number Variation and phosphorylation data for both Breast cancer and Ovarian cancer study. The majority of pathways distinguished can be confirmed by biological literature. Moreover, the proportion of correctly indentified pathways is \% higher than previous work where only mRNA-seq mutation data is incorporated for breast cancer patients. Consequently, such an in-depth pathway analysis incorporating more diverse data can give rise to the accuracy of perturbed pathway detection.

[1]  D. Morris,et al.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer , 2011, Cancer and Metastasis Reviews.

[2]  A. Adjei,et al.  Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.

[3]  I. Azimi,et al.  Calcium influx pathways in breast cancer: opportunities for pharmacological intervention , 2014, British journal of pharmacology.

[4]  L. Harris,et al.  First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. , 2001, European journal of cancer.

[5]  Eli Upfal,et al.  Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.

[6]  M. Young,et al.  Targeting AMPK for cancer prevention and treatment , 2015, Oncotarget.

[7]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[8]  M. Kasper,et al.  Hedgehog signalling in breast cancer. , 2009, Carcinogenesis.

[9]  Donald J Buchsbaum,et al.  The Wnt/β-catenin pathway in ovarian cancer: a review. , 2013, Gynecologic oncology.

[10]  Hasan H. Otu,et al.  Bayesian Pathway Analysis of Cancer Microarray Data , 2014, PloS one.

[11]  Chris Sander,et al.  Genomic complexity and AKT dependence in serous ovarian cancer. , 2012, Cancer discovery.

[12]  A. Morris,et al.  Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells Published, JLR Papers in Press, July 1, 2003. DOI 10.1194/jlr.M300188-JLR200 , 2003, Journal of Lipid Research.

[13]  L. Harris,et al.  First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. , 2001, European journal of cancer.

[14]  R. Kidd,et al.  Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment. , 2013, Breast cancer.

[15]  Stefan Wiemann,et al.  KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor , 2009, Bioinform..

[16]  C. Knabbe,et al.  TGF‐Beta Signaling in Breast Cancer , 2006, Annals of the New York Academy of Sciences.

[17]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[18]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Hwa-Yong Lee,et al.  Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype , 2015, Scientific Reports.

[20]  A. Chariot,et al.  NF-κB, stem cells and breast cancer: the links get stronger , 2011, Breast Cancer Research.

[21]  A. Leary,et al.  The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges , 2015, Chinese journal of cancer.

[22]  P. Cassoni,et al.  Oxytocin Receptor Signaling in Myoepithelial and Cancer Cells , 2005, Journal of Mammary Gland Biology and Neoplasia.

[23]  Søren Højsgaard,et al.  Graphical Independence Networks with the gRain Package for R , 2012 .

[24]  Yue Zhao,et al.  Deep pathway analysis incorporating mutation information and gene expression data , 2016, 2016 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).

[25]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[26]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[27]  Yong Lin,et al.  Tumor necrosis factor and cancer, buddies or foes? , 2008, Acta Pharmacologica Sinica.

[28]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[29]  David C. Corney,et al.  Role of p53 and Rb in ovarian cancer. , 2008, Advances in experimental medicine and biology.

[30]  S. Mabuchi,et al.  Targeting mTOR signaling pathway in ovarian cancer. , 2011, Current medicinal chemistry.

[31]  M. Quinn,et al.  Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden , 2014, BMC Cancer.

[32]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[33]  Dong-Guk Shin,et al.  A route-based pathway analysis framework integrating mutation information and gene expression data. , 2017, Methods.

[34]  H. Hondermarck,et al.  Neurotrophins and their receptors in breast cancer. , 2012, Cytokine & growth factor reviews.

[35]  Kathleen Marchal,et al.  Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration , 2015, PloS one.

[36]  Nir Friedman,et al.  Probabilistic Graphical Models - Principles and Techniques , 2009 .

[37]  Gong Yang,et al.  Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling , 2016, Cancer medicine.

[38]  A. Gerger,et al.  Hedgehog Signaling Pathway in Ovarian Cancer , 2013, International journal of molecular sciences.

[39]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[40]  I. Galve-Roperh,et al.  Involvement of the cAMP/protein kinase A pathway and of mitogen‐activated protein kinase in the anti‐proliferative effects of anandamide in human breast cancer cells , 1999, FEBS letters.

[41]  Yoon-Jae Cho,et al.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward. , 2012, Cold Spring Harbor perspectives in medicine.

[42]  S. Hilsenbeck,et al.  Hippo pathway effector Yap is an ovarian cancer oncogene. , 2010, Cancer research.

[43]  Hongzhe Li,et al.  In Response to Comment on "Network-constrained regularization and variable selection for analysis of genomic data" , 2008, Bioinform..

[44]  Joyce Lee,et al.  PI3K/Akt/mTOR inhibitors in breast cancer , 2015, Cancer biology & medicine.

[45]  Qiang Hu,et al.  Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium. , 2016, Carcinogenesis.

[46]  David N. Rider,et al.  Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer , 2011, Cancer Causes & Control.

[47]  O Sukocheva,et al.  Role of sphingolipids in oestrogen signalling in breast cancer cells: an update. , 2014, The Journal of endocrinology.

[48]  Cengizhan Ozturk,et al.  Pathway analysis of high-throughput biological data within a Bayesian network framework , 2011, Bioinform..